Western Blotting (WB), Enzyme Immunoassay (EIA), Radioimmunoassay (RIA)
Spezifität
Clone RFFVIIIC/8 is a very potent coagulation inhibitor. This antibody recognizes an epitope towards the N-terminus of full length Factor VIII. It also recognises the 210 kDa, 90 kDa and 40 kDa cleavage products. This clone does not cross-react with von Willebrand factor.
Keine Kreuzreaktivität
Maus, Hund, Ratte (Rattus)
Kreuzreaktivität (Details)
Species reactivity (tested):Human and Pig.
Aufreinigung
Affinity Chromatography on Protein G from tissue culture supernatant
ELISA: 1:200 - 1:2000. Western blotting: 1:20 - 1:200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg/mL
Buffer
PBS, 0.09 % Sodium Azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Human Factor VIII is an essential blood coagulation factor. Whilst circulating in the blood, it is mostly stably complexed to von Willebrand factor. It is activated through cleavage at various sites, dissociates from the complex and interacts with Factor IXa, in the presence of calcium ions and phospholipids, to convert Factor X to the activated Factor Xa, which activates thrombin. Thrombin cleaves fibrinogen into fibrin, which polymerises and crosslinks to form a blood clot. The activated Factor VIII is proteolytically inactivated and cleared from the bloodstream. Defects in Factor VIII cause haemophilia A, a disorder characterised by the body's inability to control blood clotting. This could result in severe blood loss, even with minor injuries.Synonyms: AHF, Antihemophilic factor, F8C, Procoagulant component